CAVEOLIN-1 AS A BIO-MARKER FOR PROSTATE CANCER

$0P50FY2002CANIH

Baylor College Of Medicine, Houston TX

Investigators

Linked publications & trials

Paper 24768607 Paper 24767770 Paper 24097862 Paper 23609828 Paper 23576558 Paper 23440425 Paper 23270728 Paper 22144662 Paper 21933889 Paper 21826097 Paper 21622724 Paper 21510904 Paper 21224358 Paper 21169414 Paper 20861284 Paper 20606036 Paper 20551310 Paper 20430421 Paper 19528467 Paper 19509179 Paper 19463689 Paper 19417030 Paper 19242612 Paper 19176382 Paper 19164898 Paper 19047084 Paper 19010869 Paper 18922926 Paper 18787043 Paper 18712736 Paper 18670643 Paper 18593949 Paper 18488029 Paper 18395973 Paper 18358473 Paper 18068632 Paper 18056169 Paper 17891175 Paper 17868773 Paper 17707459 Paper 17637743 Paper 17606710 Paper 17597184 Paper 17549413 Paper 17363522 Paper 17320698 Paper 17108143 Paper 17097719 Paper 17079484 Paper 17024109 Paper 16951141 Paper 16927306 Paper 16838179 Paper 16707439 Paper 16707417 Paper 16619264 Paper 16573373 Paper 16539836 Paper 16491480 Paper 16480930 Paper 16440331 Paper 16406988 Paper 16388505 Paper 16361440 Paper 16360458 Paper 16322684 Paper 16245277 Paper 16206286 Paper 16204060 Paper 16140968 Paper 16123302 Paper 16015593 Paper 16000564 Paper 15879782 Paper 15806576 Paper 15774789 Paper 15712208 Paper 15538284 Paper 15475446 Paper 15448004 Paper 15342391 Paper 15338010 Paper 15305341 Paper 15280533 Paper 15256439 Paper 15247716 Paper 15223964 Paper 15145177 Paper 15129429 Paper 15076291 Paper 15050332 Paper 15044961 Paper 15026346 Paper 14743470 Paper 14716745 Paper 14688378 Paper 14645548 Paper 14633713 Paper 14581350 Paper 14560019

Abstract

DESCRIPTION (provided by applicant): Caveolin-1 is an integral protein of caveolae, known to play important roles in signal transduction and lipid transport. We have documented that caveolin-1 (cav-1) expression is increased in metastatic prostate cancer and is also increased in primary and metastatic human prostate cancer following androgen ablation therapy. We have also shown that the level of cav-1 expression in radical prostatectomy specimens is predictive of recurrence and is higher in African-American men. Recently, we have shown that cav-1 is secreted by androgen-insensitive prostate cancer cells and have developed an indirect sandwich ELISA to measure the level of cav-1 in serum. We propose to exploit the expression and selective secretion of cav-1 by aggressive prostate cancer cells toward the development of novel prognostic tests for prostate cancer progression. Initially we will correlate tissue (needle biopsy and radical prostatectomy specimens) and serum cav-1 in a panel of prostate cancer patients and controls to determine the sensitivity and specificity of our assays. We will further conduct a retrospective cohort study to assess the predictive value of pre-operative tissue and serum cav-1 levels in regard to pathologic features of the cancer and biochemical (serum PSA) recurrence. We will also conduct a prospective population-based study involving men enrolled in the BCM SPORE who have been diagnosed with prostate cancer and who will undergo a radical prostatectomy at our institution. This study will provide important information regarding the capacity of tissue and/or serum cav-1 levels to identify aggressive disease prior to treatment. Finally we will conduct a retrospective study that will assess the value of serum cav-1 levels as a risk factor for the development of prostate cancer. This study will be an ancillary study to the therosclerosis Risk in Communities (ARIC) study cohort.

View original record on NIH RePORTER →